Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Shares Outstanding (Weighted Average) (2016 - 2025)

RedHill Biopharma has reported Shares Outstanding (Weighted Average) over the past 15 years, most recently at $147.6 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) fell 98.8% to $147.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $147.6 million through Dec 2025, down 98.8% year-over-year, with the annual reading at $147.6 million for FY2025, 98.8% down from the prior year.
  • Shares Outstanding (Weighted Average) was $147.6 million for Q4 2025 at RedHill Biopharma, up from $18.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $12.3 billion in Q4 2024 and troughed at $1.3 million in Q2 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $2.8 million (2023), against an average of $1.1 billion.
  • Year-over-year, Shares Outstanding (Weighted Average) soared 2621.98% in 2024 and then tumbled 98.8% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $465.3 million in 2021, then soared by 32.46% to $616.3 million in 2022, then soared by 320.45% to $2.6 billion in 2023, then surged by 375.56% to $12.3 billion in 2024, then tumbled by 98.8% to $147.6 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Shares Outstanding (Weighted Average) are $147.6 million (Q4 2025), $18.0 million (Q2 2025), and $12.3 billion (Q4 2024).